Feb 15 (Reuters) - Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis, the company said on Thursday. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
The $50 million purchase could turn into Nvidia's biggest investment.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
AI could generate trillions of dollars over the next ten years. One company is already an early winner of this windfall.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
The bank CEO says the company looks for candidates who are “smart, ethical, decent people.”